RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00050348.xml
PDF herunterladen
CC BY 4.0 · Indian J Med Paediatr Oncol 2023; 44(01): 084-092
DOI: 10.1055/s-0042-1759718
DOI: 10.1055/s-0042-1759718
Review Article
Imaging Recommendations for Diagnosis, Staging, and Management of Renal Tumors
Authors
Abstract
Renal cell carcinomas accounts for 2% of all the cancers globally. Most of the renal tumors are detected incidentally. Ultrasound remains the main screening modality to evaluate the renal masses. A multi -phase contrast enhanced computer tomography is must for characterizing the renal lesions. Imaging plays an important role in staging, treatment planning and follow up of renal cancers. In this review , we discuss the imaging guidelines for the management of renal tumors.
Publikationsverlauf
Artikel online veröffentlicht:
06. März 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1
Bray F,
Ferlay J,
Soerjomataram I,
Siegel RL,
Torre LA,
Jemal A.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
Reference Ris Wihthout Link
- 2 Kabel AM, Zamzami F, Al-Talhi M, Al-Dwila K, Habib R. Renal cell carcinoma: insights into risk factors, diagnosis and management. J Cancer Research Treatment 2017; 5: 15-19
- 3
Padala SA,
Barsouk A,
Thandra KC.
et al.
Epidemiology of renal cell carcinoma. World J Oncol 2020; 11 (03) 79-87
Reference Ris Wihthout Link
- 4 Heng DYC, Xie W, Regan MM. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27 (34) 5794-5799
- 5 Ko JJ, Xie W, Kroeger N. et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 2015; 16 (03) 293-300
- 6 Bertolotto M, Bucci S, Valentino M, Currò F, Sachs C, Cova MA. Contrast-enhanced ultrasound for characterizing renal masses. Eur J Radiol 2018; 105: 41-48
- 7 Sidhu PS, Cantisani V, Dietrich CF. et al. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: update 2017 (Long Version). Ultraschall Med 2018; 39 (02) e2-e44
- 8 Clevert D-A, Minaifar N, Weckbach S. et al. Multislice computed tomography versus contrast-enhanced ultrasound in evaluation of complex cystic renal masses using the Bosniak classification system. Clin Hemorheol Microcirc 2008; 39 (1-4): 171-178
- 9 Cantisani V, Bertolotto M, Clevert D-A. et al. EFSUMB 2020 proposal for a contrast-enhanced ultrasound-adapted Bosniak cyst categorization - position statement. Ultraschall Med 2021; 42 (02) 154-166
- 10 Wang ZJ, Nikolaidis P, Khatri G. et al; Expert Panel on Urologic Imaging. ACR Appropriateness Criteria® Indeterminate Renal Mass. J Am Coll Radiol 2020; 17 (11S): S415-S428
- 11 Meloni MF, Bertolotto M, Alberzoni C. et al. Follow-up after percutaneous radiofrequency ablation of renal cell carcinoma: contrast-enhanced sonography versus contrast-enhanced CT or MRI. AJR Am J Roentgenol 2008; 191 (04) 1233-1238
- 12 Vikram R, Beland MD, Blaufox MD. et al. ACR appropriateness criteria renal cell carcinoma staging. J Am Coll Radiol 2016; 13 (05) 518-525
- 13 Li Q, Wang Z, Ma X, Tang J, Luo Y. Diagnostic accuracy of contrast-enhanced ultrasound for detecting bland thrombus from inferior vena cava tumor thrombus in patients with renal cell carcinoma. Int Braz J Urol 2020; 46 (01) 92-100
- 14 Ljungberg B, Albiges L, Abu-Ghanem Y. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2022 update. Eur Urol 2022; 82 (04) 399-410
- 15 Ward RD, Tanaka H, Campbell SC, Remer EM. 2017 AUA renal mass and localized renal cancer guidelines: imaging implications. Radiographics 2018; 38 (07) 2021-2033
- 16 Pedrosa I, Cadeddu JA. How we do it: managing the indeterminate renal mass with the MRI clear cell likelihood score. Radiology 2022; 302 (02) 256-269
- 17 Silverman SG, Pedrosa I, Ellis JH. et al. Bosniak classification of cystic renal masses, Version 2019: an update proposal and needs assessment. Radiology 2019; 292 (02) 475-488
- 18 Birnbaum BA, Hindman N, Lee J, Babb JS. Renal cyst pseudoenhancement: influence of multidetector CT reconstruction algorithm and scanner type in phantom model. Radiology 2007; 244 (03) 767-775
- 19 Lim DJ, Carter MF. Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. J Urol 1993; 150 (04) 1112-1114
- 20 Mano R, Vertosick E, Sankin AI. et al. Subcentimeter pulmonary nodules are not associated with disease progression in patients with renal cell carcinoma. J Urol 2015; 193 (03) 776-782
- 21 Kotecha RR, Flippot R, Nortman T. et al. Prognosis of incidental brain metastases in patients with advanced renal cell carcinoma. J Natl Compr Canc Netw 2021; 19 (04) 432-438
- 22 Dilauro M, Quon M, McInnes MDF. et al. Comparison of contrast-enhanced multiphase renal protocol CT versus MRI for diagnosis of papillary renal cell carcinoma. AJR Am J Roentgenol 2016; 206 (02) 319-325
- 23 Schieda N, Lim RS, McInnes MDF. et al. Characterization of small (<4cm) solid renal masses by computed tomography and magnetic resonance imaging: current evidence and further development. Diagn Interv Imaging 2018; 99 (7-8): 443-455
- 24 Herts BR, Silverman SG, Hindman NM. et al. Management of the incidental renal mass on CT: a white paper of the ACR incidental findings committee. J Am Coll Radiol 2018; 15 (02) 264-273
- 25 Krishna S, Schieda N, Pedrosa I. et al. Update on MRI of cystic renal masses including Bosniak Version 2019. J Magn Reson Imaging 2021; 54 (02) 341-356
- 26 Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27 (05) 612-624
- 27 Roy C, Sauer B, Lindner V, Lang H, Saussine C, Jacqmin D. MR imaging of papillary renal neoplasms: potential application for characterization of small renal masses. Eur Radiol 2007; 17 (01) 193-200
- 28 Cornelis F, Grenier N. Multiparametric magnetic resonance imaging of solid renal tumors: a practical algorithm. Semin Ultrasound CT MR 2017; 38 (01) 47-58
- 29 Tsili AC, Andriotis E, Gkeli MG. et al; Oncologic Imaging Subcommittee Working Group of the Hellenic Radiological Society. The role of imaging in the management of renal masses. Eur J Radiol 2021; 141: 109777 https://www.ejradiology.com/article/S0720-048X(21)00258-8/fulltext [Internet]
- 30 Yang C-W, Shen S-H, Chang Y-H. et al. Are there useful CT features to differentiate renal cell carcinoma from lipid-poor renal angiomyolipoma?. AJR Am J Roentgenol 2013; 201 (05) 1017-1028
- 31 Galia M, Albano D, Bruno A. et al. Imaging features of solid renal masses. Br J Radiol 2017; 90 (1077): 20170077
- 32 Low G, Huang G, Fu W, Moloo Z, Girgis S. Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol 2016; 8 (05) 484-500
- 33 Servaes SE, Hoffer FA, Smith EA, Khanna G. Imaging of Wilms tumor: an update. Pediatr Radiol 2019; 49 (11) 1441-1452
- 34 Wang H-Y, Ding H-J, Chen J-H. et al. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging 2012; 12: 464-474
- 35 Liu Y. The place of FDG PET/CT in renal cell carcinoma: value and limitations. Front Oncol 2016; 6: 201
- 36 Petrelli F, Coinu A, Vavassori I. et al. Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis. Clin Genitourin Cancer 2016; 14 (06) 465-472
- 37 Pindoria N, Raison N, Blecher G, Catterwell R, Dasgupta P. Cytoreductive nephrectomy in the era of targeted therapies: a review. BJU Int 2017; 120 (03) 320-328
- 38
Amin MB,
Greene FL,
Edge SB.
et al.
The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a
population-based to a more “personalized” approach to cancer staging. CA Cancer J
Clin 2017; 67: 93-9
Reference Ris Wihthout Link
- 39 Ljungberg B, Albiges L, Abu-Ghanem Y. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2019 update. Eur Urol 2019; 75 (05) 799-810
- 40 Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am 2008; 35 (04) 613-625 , vii vii
- 41 Sun M, Vetterlein M, Harshman LC, Chang SL, Choueiri TK, Trinh Q-D. Risk assessment in small renal masses: a review article. Urol Clin North Am 2017; 44 (02) 189-202
- 42 Martínez-Salamanca JI, Huang WC, Millán I. et al; International Renal Cell Carcinoma-Venous Thrombus Consortium. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol 2011; 59 (01) 120-127
- 43 Margulis V, Sánchez-Ortiz RF, Tamboli P, Cohen DD, Swanson DA, Wood CG. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer 2007; 109 (10) 2025-2030
- 44 Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol Pract 2022; 18 (03) 187-196
- 45 Campbell SC, Novick AC, Belldegrun A. et al; Practice Guidelines Committee of the American Urological Association. Guideline for management of the clinical T1 renal mass. J Urol 2009; 182 (04) 1271-1279
- 46 Lee Z, Jegede OA, Haas NB. et al. Local recurrence following resection of intermediate-high risk nonmetastatic renal cell carcinoma: an anatomical classification and analysis of the ASSURE (ECOG-ACRIN E2805) adjuvant trial. J Urol 2020; 203 (04) 684-689
- 47 Thomas AZ, Adibi M, Borregales LD. et al. Surgical management of local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy. J Urol 2015; 194 (02) 316-322
- 48 Donat SM, Diaz M, Bishoff JT. et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol 2013; 190 (02) 407-416
- 49 Antonelli A, Furlan M, Tardanico R. et al. Features of ipsilateral renal recurrences after partial nephrectomy: a proposal of a pathogenetic classification. Clin Genitourin Cancer 2017; 15 (05) 540-547
- 50 Johnson A, Sudarshan S, Liu J, Linehan WM, Pinto PA, Bratslavsky G. Feasibility and outcomes of repeat partial nephrectomy. J Urol 2008; 180 (01) 89-93 , discussion 93
- 51 Marchioni M, Sountoulides P, Furlan M. et al. Management of local recurrence after radical nephrectomy: surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohort. Int Urol Nephrol 2021; 53 (11) 2273-2280
- 52 Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 2000; 164 (02) 322-325
- 53 Ierardi AM, Carnevale A, Rossi UG. et al. Percutaneous microwave ablation therapy of renal cancer local relapse after radical nephrectomy: a feasibility and efficacy study. Med Oncol 2020; 37 (04) 27